Tscan therapeutics announces closing of public offering

Waltham, mass., june 01, 2023 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t cell receptor (tcr)-engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced the closing of an underwritten public offering of 23,287,134 shares of its voting common stock, at a public offering price of $2.00 per share, and pre-funded warrants to purchase up to an aggregate of 47,010,526 shares of its voting common stock at a price to the public of $1.9999 per pre-funded warrant, which represents the per share public offering price for the voting common stock less the $0.0001 per share exercise price for each such pre-funded warrant. the gross proceeds to tscan from this offering, including the partial exercise of the underwriters' over allotment option, were approximately $140.6 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by tscan.
TCRX Ratings Summary
TCRX Quant Ranking